002462 Stock Overview
Engages in the wholesale, retail, and logistics of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Cachet Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.72 |
| 52 Week High | CN¥15.30 |
| 52 Week Low | CN¥9.78 |
| Beta | 0.37 |
| 1 Month Change | -2.35% |
| 3 Month Change | 31.54% |
| 1 Year Change | -2.42% |
| 3 Year Change | 5.38% |
| 5 Year Change | -12.56% |
| Change since IPO | -64.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002462 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -2.7% | -2.2% | -1.2% |
| 1Y | -2.4% | -7.7% | 11.8% |
Return vs Industry: 002462 exceeded the CN Healthcare industry which returned -7.7% over the past year.
Return vs Market: 002462 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002462 volatility | |
|---|---|
| 002462 Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 8.3% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002462 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002462's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2,357 | Yibin Huang | www.cachet.com.cn |
Cachet Pharmaceutical Co., Ltd. engages in the wholesale, retail, and logistics of pharmaceutical products in China. It also sells medical devices. Cachet Pharmaceutical Co., Ltd.
Cachet Pharmaceutical Co., Ltd. Fundamentals Summary
| 002462 fundamental statistics | |
|---|---|
| Market cap | CN¥4.00b |
| Earnings (TTM) | CN¥244.17m |
| Revenue (TTM) | CN¥26.70b |
16.4x
P/E Ratio0.1x
P/S RatioIs 002462 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002462 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.70b |
| Cost of Revenue | CN¥25.13b |
| Gross Profit | CN¥1.56b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥244.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.84 |
| Gross Margin | 5.86% |
| Net Profit Margin | 0.91% |
| Debt/Equity Ratio | 45.0% |
How did 002462 perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 14:19 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cachet Pharmaceutical Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhouyu Deng | BOCI Research Ltd. |
| Weiya Zhang | BOCI Research Ltd. |
| Wei Xuan Huang | Changjiang Securities Co. LTD. |